These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11966680)

  • 21. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.
    Imai J; Ieiri I; Mamiya K; Miyahara S; Furuumi H; Nanba E; Yamane M; Fukumaki Y; Ninomiya H; Tashiro N; Otsubo K; Higuchi S
    Pharmacogenetics; 2000 Feb; 10(1):85-9. PubMed ID: 10739176
    [No Abstract]   [Full Text] [Related]  

  • 22. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
    Lee CR; Goldstein JA; Pieper JA
    Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic modulation of oral anticoagulation with warfarin.
    Margaglione M; Colaizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di Minno G
    Thromb Haemost; 2000 Nov; 84(5):775-8. PubMed ID: 11127854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Avoiding overanticoagulation: pharmacogenomics or pragmatism?
    Baglin T
    Thromb Haemost; 2001 May; 85(5):945-6. PubMed ID: 11372698
    [No Abstract]   [Full Text] [Related]  

  • 26. Genetic analysis of CYP2C9 polymorphism in a Japanese population.
    Nasu K; Kubota T; Ishizaki T
    Pharmacogenetics; 1997 Oct; 7(5):405-9. PubMed ID: 9352578
    [No Abstract]   [Full Text] [Related]  

  • 27. Genetic association between sensitivity to warfarin and expression of CYP2C9*3.
    Steward DJ; Haining RL; Henne KR; Davis G; Rushmore TH; Trager WF; Rettie AE
    Pharmacogenetics; 1997 Oct; 7(5):361-7. PubMed ID: 9352571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.
    Leung AY; Chow HC; Kwong YL; Lie AK; Fung AT; Chow WH; Yip AS; Liang R
    Blood; 2001 Oct; 98(8):2584-7. PubMed ID: 11588061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
    Borlak J; Thum T
    Clin Chem; 2002 Sep; 48(9):1592-4. PubMed ID: 12194942
    [No Abstract]   [Full Text] [Related]  

  • 31. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.
    Yasar U; Eliasson E; Dahl ML
    Carcinogenesis; 2002 Apr; 23(4):665; author reply 667-8. PubMed ID: 11960920
    [No Abstract]   [Full Text] [Related]  

  • 32. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.
    Henne KR; Gaedigk A; Gupta G; Leeder JS; Rettie AE
    J Chromatogr B Biomed Sci Appl; 1998 Jun; 710(1-2):143-8. PubMed ID: 9686881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County.
    London SJ; Sullivan-Klose T; Daly AK; Idle JR
    Pharmacogenetics; 1997 Oct; 7(5):401-4. PubMed ID: 9352577
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
    van der Weide J; Steijns LS; van Weelden MJ; de Haan K
    Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic control of anticoagulation.
    Mannucci PM
    Lancet; 1999 Feb; 353(9154):688-9. PubMed ID: 10073506
    [No Abstract]   [Full Text] [Related]  

  • 36. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
    Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
    Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic susceptibility to hemorrhagic complications during warfarin therapy.
    Tabrizi AR; Freeman BD; Buchman TG; Zehnbauer BA
    Surgery; 2001 May; 129(5):645-6. PubMed ID: 11331459
    [No Abstract]   [Full Text] [Related]  

  • 38. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.
    Rettie AE; Haining RL; Bajpai M; Levy RH
    Epilepsy Res; 1999 Jul; 35(3):253-5. PubMed ID: 10413320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.
    Hanatani T; Fukuda T; Ikeda M; Imaoka S; Hiroi T; Funae Y; Azuma J
    Pharmacogenomics J; 2001; 1(4):288-92. PubMed ID: 11908770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.
    Scordo MG; Aklillu E; Yasar U; Dahl ML; Spina E; Ingelman-Sundberg M
    Br J Clin Pharmacol; 2001 Oct; 52(4):447-50. PubMed ID: 11678789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.